Analysts Anticipate SeaSpine Holdings Corp (SPNE) Will Post Quarterly Sales of $36.66 Million
Equities analysts predict that SeaSpine Holdings Corp (NASDAQ:SPNE) will announce sales of $36.66 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for SeaSpine’s earnings. The highest sales estimate is $37.10 million and the lowest is $36.22 million. SeaSpine reported sales of $33.98 million during the same quarter last year, which indicates a positive year-over-year growth rate of 7.9%. The firm is expected to announce its next quarterly earnings report on Wednesday, February 27th.
On average, analysts expect that SeaSpine will report full-year sales of $142.07 million for the current year, with estimates ranging from $141.64 million to $142.50 million. For the next year, analysts expect that the business will report sales of $157.38 million, with estimates ranging from $152.27 million to $162.50 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover SeaSpine.
SeaSpine (NASDAQ:SPNE) last announced its quarterly earnings data on Tuesday, November 6th. The medical equipment provider reported ($0.65) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.53) by ($0.12). SeaSpine had a negative return on equity of 30.81% and a negative net margin of 22.60%. The business had revenue of $35.83 million for the quarter, compared to analyst estimates of $35.56 million.
In other news, Director John B. Henneman III sold 3,407 shares of the company’s stock in a transaction on Wednesday, August 29th. The stock was sold at an average price of $14.65, for a total value of $49,912.55. Following the sale, the director now directly owns 60,144 shares in the company, valued at $881,109.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director John B. Henneman III sold 4,564 shares of the company’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $14.72, for a total value of $67,182.08. Following the completion of the sale, the director now owns 60,144 shares in the company, valued at $885,319.68. The disclosure for this sale can be found here. 13.54% of the stock is currently owned by corporate insiders.
Large investors have recently modified their holdings of the company. Rhumbline Advisers purchased a new stake in shares of SeaSpine in the second quarter valued at $134,000. Northern Trust Corp lifted its position in SeaSpine by 35.3% during the first quarter. Northern Trust Corp now owns 35,512 shares of the medical equipment provider’s stock worth $360,000 after buying an additional 9,271 shares during the period. Bank of New York Mellon Corp lifted its position in SeaSpine by 261.4% during the second quarter. Bank of New York Mellon Corp now owns 37,185 shares of the medical equipment provider’s stock worth $470,000 after buying an additional 26,895 shares during the period. Schwab Charles Investment Management Inc. lifted its position in SeaSpine by 99.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 46,267 shares of the medical equipment provider’s stock worth $584,000 after buying an additional 23,090 shares during the period. Finally, Wedge Capital Management L L P NC purchased a new position in SeaSpine during the second quarter worth about $734,000. Institutional investors and hedge funds own 42.11% of the company’s stock.
SPNE stock traded up $0.90 on Friday, reaching $16.27. 2,731 shares of the company’s stock were exchanged, compared to its average volume of 97,020. SeaSpine has a twelve month low of $8.76 and a twelve month high of $18.42. The firm has a market capitalization of $284.85 million, a PE ratio of -6.16 and a beta of 0.19. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.91 and a quick ratio of 1.31.
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical regions of the spine.
Recommended Story: Dividend Stocks – Are They Right For You?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SeaSpine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SeaSpine and related companies with MarketBeat.com's FREE daily email newsletter.